NCT04562792View on ClinicalTrials.gov

Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

May 8, 2020

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Relapsed Pediatric ALLRelapsed Pediatric AMLRefractory Acute Myeloid LeukemiaRefractory Acute Lymphoblastic Leukemia
Interventions
DRUG

Daunorubicin

Eligible patients with relapsed and/or refractory acute leukemia will receive daunorubicin 6.75mg/m2 daily for 5 consecutive days.

Trial Locations (1)

64108

Children's Mercy Hospital, Kansas City

All Listed Sponsors
lead

Children's Mercy Hospital Kansas City

OTHER

NCT04562792 - Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia | Biotech Hunter | Biotech Hunter